Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (1): 41-46.DOI: 10.3969/j.issn.1673-8640.2022.01.008
Previous Articles Next Articles
MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan()
Received:
2021-05-20
Revised:
2021-09-22
Online:
2022-01-30
Published:
2022-03-07
Contact:
CUI Fan
CLC Number:
MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer[J]. Laboratory Medicine, 2022, 37(1): 41-46.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.01.008
组别 | 例数 | E-Cad/ (ng/mL) | G-17/ (pg/mL) | HER-2阳性/ [例(%)] |
---|---|---|---|---|
胃癌组 | 92 | 20.92±5.11 | 25.68±6.33 | 27(29.35) |
对照组 | 92 | 32.76±4.14 | 10.67±3.22 | 5(5.43) |
统计值 | 17.268 | 20.272 | 20.950 | |
P值 | 0.000 | 0.000 | 0.000 |
组别 | 例数 | E-Cad/ (ng/mL) | G-17/ (pg/mL) | HER-2阳性/ [例(%)] |
---|---|---|---|---|
胃癌组 | 92 | 20.92±5.11 | 25.68±6.33 | 27(29.35) |
对照组 | 92 | 32.76±4.14 | 10.67±3.22 | 5(5.43) |
统计值 | 17.268 | 20.272 | 20.950 | |
P值 | 0.000 | 0.000 | 0.000 |
临床病理 参数 | 例数 | E-Cad/(ng/mL) | G-17/ (pg/mL) | HER-2阳性/ [例(%)] | 临床病理参数 | 例数 | E-Cad/ (ng/mL) | G-17/ (pg/mL) | HER-2阳性/ [例(%)] |
---|---|---|---|---|---|---|---|---|---|
性别 | 分化情况 | ||||||||
男性 | 55 | 20.47±0.30 | 26.37±1.41 | 15(27.27) | 低分化 | 35 | 16.42±5.88 | 23.09±5.14 | 2(5.71) |
女性 | 37 | 20.42±0.21 | 26.09±1.46 | 12(32.43) | 中分化 | 30 | 19.10±4.87 | 26.08±5.17 | 4(13.33) |
统计值 | 0.940 | 0.914 | 0.123 | 高分化 | 27 | 22.10±4.87 | 29.55±5.17 | 21(77.78) | |
P值 | 0.350 | 0.360 | 0.940 | 统计值 | 12.090 | 11.202 | 17.989 | ||
TNM分期 | P值 | 0.000 | 0.000 | 0.000 | |||||
Ⅰ~Ⅱ期 | 45 | 17.01±5.42 | 23.69±1.15 | 5(11.11) | 是否复发 | ||||
Ⅲ~Ⅳ期 | 47 | 22.03±5.55 | 29.79±1.14 | 22(46.81) | 复发 | 25 | 18.74±5.37 | 28.33±1.33 | 18(72.00) |
统计值 | 4.389 | 24.704 | 11.222 | 未复发 | 67 | 21.73±5.51 | 24.69±1.57 | 9(1.00) | |
P值 | 0.000 | 0.000 | 0.000 | 统计值 | 2.359 | 16.968 | 30.122 | ||
P值 | 0.020 | 0.000 | 0.000 |
临床病理 参数 | 例数 | E-Cad/(ng/mL) | G-17/ (pg/mL) | HER-2阳性/ [例(%)] | 临床病理参数 | 例数 | E-Cad/ (ng/mL) | G-17/ (pg/mL) | HER-2阳性/ [例(%)] |
---|---|---|---|---|---|---|---|---|---|
性别 | 分化情况 | ||||||||
男性 | 55 | 20.47±0.30 | 26.37±1.41 | 15(27.27) | 低分化 | 35 | 16.42±5.88 | 23.09±5.14 | 2(5.71) |
女性 | 37 | 20.42±0.21 | 26.09±1.46 | 12(32.43) | 中分化 | 30 | 19.10±4.87 | 26.08±5.17 | 4(13.33) |
统计值 | 0.940 | 0.914 | 0.123 | 高分化 | 27 | 22.10±4.87 | 29.55±5.17 | 21(77.78) | |
P值 | 0.350 | 0.360 | 0.940 | 统计值 | 12.090 | 11.202 | 17.989 | ||
TNM分期 | P值 | 0.000 | 0.000 | 0.000 | |||||
Ⅰ~Ⅱ期 | 45 | 17.01±5.42 | 23.69±1.15 | 5(11.11) | 是否复发 | ||||
Ⅲ~Ⅳ期 | 47 | 22.03±5.55 | 29.79±1.14 | 22(46.81) | 复发 | 25 | 18.74±5.37 | 28.33±1.33 | 18(72.00) |
统计值 | 4.389 | 24.704 | 11.222 | 未复发 | 67 | 21.73±5.51 | 24.69±1.57 | 9(1.00) | |
P值 | 0.000 | 0.000 | 0.000 | 统计值 | 2.359 | 16.968 | 30.122 | ||
P值 | 0.020 | 0.000 | 0.000 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 敏感性/% | 阳性预测值/% | 阴性预测值/% | Youden指数 |
---|---|---|---|---|---|---|---|---|
E-Cad | 0.775(0.520~0.872) | 15.32 ng/mL | 92.59 | 40.48 | 92.59 | 34.25 | 89.47 | 33.07 |
G-17 | 0.822(0.230~0.974) | 22.71 ng/mL | 81.48 | 51.11 | 81.48 | 34.38 | 82.14 | 32.59 |
HER-2 | 0.603(0.600~0.746) | 2+ | 88.89 | 35.14 | 88.89 | 31.58 | 81.25 | 24.03 |
联合检测 | 0.950(0.112~0.965) | 0.64 | 77.78 | 74.07 | 77.78 | 80.77 | 90.91 | 51.85 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | 敏感性/% | 阳性预测值/% | 阴性预测值/% | Youden指数 |
---|---|---|---|---|---|---|---|---|
E-Cad | 0.775(0.520~0.872) | 15.32 ng/mL | 92.59 | 40.48 | 92.59 | 34.25 | 89.47 | 33.07 |
G-17 | 0.822(0.230~0.974) | 22.71 ng/mL | 81.48 | 51.11 | 81.48 | 34.38 | 82.14 | 32.59 |
HER-2 | 0.603(0.600~0.746) | 2+ | 88.89 | 35.14 | 88.89 | 31.58 | 81.25 | 24.03 |
联合检测 | 0.950(0.112~0.965) | 0.64 | 77.78 | 74.07 | 77.78 | 80.77 | 90.91 | 51.85 |
项目 | β值 | 标准误 | Wald值 | HR①值(95%CI) | P值 |
---|---|---|---|---|---|
年龄 | |||||
<65.71岁 | |||||
≥65.71岁 | 0.030 | 0.150 | 0.870 | 1.012(0.982~1.054) | 0.042 |
性别 | |||||
女性 | |||||
男性 | -0.050 | 0.420 | 0.020 | 0.982(0.431~2.095) | 0.934 |
肿瘤大小 | |||||
<4 cm | |||||
≥4 cm | 0.390 | 0.420 | 1.140 | 1.493(0.705~3.211) | 0.591 |
分化情况 | |||||
低分化 | |||||
中高分化 | -0.458 | 0.425 | 2.232 | 0.623(0.218~1.347) | 0.120 |
TNM分期 | |||||
Ⅰ~Ⅱ期 | |||||
Ⅲ~Ⅳ期 | -0.958 | 0.417 | 3.528 | 1.127(0.889~1.712) | 0.032 |
E-Cad | -0.180 | 0.043 | 17.423 | 0.835(0.767~0.909) | 0.000 |
G-17 | 0.450 | 0.099 | 20.652 | 1.568(1.292~1.904) | 0.000 |
HER-2 | 1.381 | 0.497 | 7.736 | 3.981(1.504~10.538) | 0.005 |
项目 | β值 | 标准误 | Wald值 | HR①值(95%CI) | P值 |
---|---|---|---|---|---|
年龄 | |||||
<65.71岁 | |||||
≥65.71岁 | 0.030 | 0.150 | 0.870 | 1.012(0.982~1.054) | 0.042 |
性别 | |||||
女性 | |||||
男性 | -0.050 | 0.420 | 0.020 | 0.982(0.431~2.095) | 0.934 |
肿瘤大小 | |||||
<4 cm | |||||
≥4 cm | 0.390 | 0.420 | 1.140 | 1.493(0.705~3.211) | 0.591 |
分化情况 | |||||
低分化 | |||||
中高分化 | -0.458 | 0.425 | 2.232 | 0.623(0.218~1.347) | 0.120 |
TNM分期 | |||||
Ⅰ~Ⅱ期 | |||||
Ⅲ~Ⅳ期 | -0.958 | 0.417 | 3.528 | 1.127(0.889~1.712) | 0.032 |
E-Cad | -0.180 | 0.043 | 17.423 | 0.835(0.767~0.909) | 0.000 |
G-17 | 0.450 | 0.099 | 20.652 | 1.568(1.292~1.904) | 0.000 |
HER-2 | 1.381 | 0.497 | 7.736 | 3.981(1.504~10.538) | 0.005 |
项目 | β值 | 标准误 | Wald值 | HR值(95%CI) | P值 |
---|---|---|---|---|---|
年龄 | 0.008 | 0.402 | 0.508 | 0.958(0.425~1.858) | 0.884 |
TNM分期(Ⅲ~Ⅳ期) | -1.258 | 0.368 | 6.135 | 0.292(0.139~0.714) | 0.027 |
E-Cad(降低) | -0.125 | 0.038 | 15.247 | 0.745(0.664~0.985) | 0.002 |
G-17(升高) | 0.368 | 0.540 | 1.643 | 1.997(0.658~4.328) | 0.020 |
HER-2[阳性(2+~3+)] | 0.687 | 0.358 | 6.235 | 2.895(0.548~7.758) | 0.012 |
项目 | β值 | 标准误 | Wald值 | HR值(95%CI) | P值 |
---|---|---|---|---|---|
年龄 | 0.008 | 0.402 | 0.508 | 0.958(0.425~1.858) | 0.884 |
TNM分期(Ⅲ~Ⅳ期) | -1.258 | 0.368 | 6.135 | 0.292(0.139~0.714) | 0.027 |
E-Cad(降低) | -0.125 | 0.038 | 15.247 | 0.745(0.664~0.985) | 0.002 |
G-17(升高) | 0.368 | 0.540 | 1.643 | 1.997(0.658~4.328) | 0.020 |
HER-2[阳性(2+~3+)] | 0.687 | 0.358 | 6.235 | 2.895(0.548~7.758) | 0.012 |
[1] | 刘苗, 王英南, 张韶辰, 等. 影响胃癌根治术后早期复发的危险因素分析[J]. 临床肿瘤学杂志, 2020, 25(10):905-910. |
[2] | 刘苗, 王英南, 赵群, 等. 不同Lauren分型胃癌的临床病理特征及影响胃癌根治术后复发的危险因素分析[J]. 中国肿瘤, 2019, 28(12):941-950. |
[3] | MA L, YANG R, GU J, et al. The expression of AGGF1,FOXC2,and E-cadherin in esophageal carcinoma and their clinical significance[J]. Medicine(Baltimore), 2020, 99(37):e22173. |
[4] |
SYMMANS W F, WEI C, GOULD R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype[J]. J Clin Oncol, 2017, 35(10):1049-1060.
DOI URL |
[5] |
POKHAREL K, GILBAR P J, MANSFIELD S K, et al. Elevated beta human chorionic gonadotropin in a non-pregnant female diagnosed with anal squamous cell carcinoma[J]. J Oncol Pharm Pract, 2020, 26(5):1266-1269.
DOI URL |
[6] | ZHAO W X, LIU Z F, LI X L, et al. Correlations of serum homocysteine,VEGF and gastrin 17 with gastric cancer and precancerous lesions[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10):4192-4198. |
[7] |
ZHOU N, GUO X, YANG M, et al. 68Ga-ZHER2 PET/CT reveals HER2-positive metastatic gastric cancer with better image quality than 18F-FDG[J]. Clin Nuclear Med, 2020, 45(2):e101-e102.
DOI URL |
[8] |
ULASE D, HECKL S, BEHRENS H M, et al. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference[J]. Histopathology, 2020, 76(3):433-446.
DOI URL |
[9] |
BAROK M, LE JONCOUR V, MARTINS A, et al. ARX788,a novel anti-HER2 antibody-drug conjugate,shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer[J]. Cancer Lett, 2020, 473:156-163.
DOI URL |
[10] | 张自森, 巴楠, 张剑, 等. 胃癌FOLFOX4方案化疗患者预后与血清可溶性E-钙黏蛋白表达的关系[J]. 中华实验外科杂志, 2016, 33(12):2773-2775. |
[11] | 张毅, 张君薇. 血清E-Cad、PGⅠ、CEA和CA19-9单独和联合检测对胃癌诊断的临床价值[J]. 实用癌症杂志, 2018, 33(3):370-372. |
[12] | 陈玲, 林晶, 王晓杰, 等. 人类表皮生长因子受体2在胃癌根治术后复发患者中的表达及其意义[J]. 肿瘤研究与临床, 2020, 32(3):178-181. |
[13] | TORABIZADEH Z, NOSRATI A, SAJADI SARAVI S N, et al. Evaluation of E-cadherin expression in gastric cancer and its correlation with clinicopathologic parameters[J]. Int J Hematol Oncol Stem Cell Res, 2017, 11(2):158-164. |
[14] |
LIN Z, BIAN H, CHEN C, et al. Application of serum pepsinogen and carbohydrate antigen 72-4(CA72-4) combined with gastrin-17(G-17) detection in the screening,diagnosis,and evaluation of early gastric cancer[J]. J Gastrointest Oncol, 2021, 12(3):1042-1048.
DOI URL |
[15] | WANG Y, ZHU Z, LIU Z, et al. Diagnostic value of serum pepsinogen Ⅰ,pepsinogen Ⅱ,and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826. |
[16] | 董曲文, 陈晓, 丁纪元. 早期胃癌患者内镜黏膜下剥离术前后血清胃泌素-17、糖类抗原-125及胃蛋白酶原水平的变化和意义[J]. 中国内镜杂志, 2020, 26(2):37-42. |
[17] |
PALLE J, ROCHAND A, PERNOT S, et al. Human epidermal growth factor receptor 2(HER2) in advanced gastric cancer:current knowledge and future perspectives[J]. Drugs, 2020, 80(4):401-415.
DOI URL |
[18] |
KANAYAMA K, IMAI H, USUGI E, et al. Association of HER2 gene amplification and tumor progression in early gastric cancer[J]. Virchows Arch, 2018, 473(5):559-565.
DOI URL |
[19] |
KIM S, KIM Y J, CHUNG W C. HER-2 positivity is a high risk of recurrence of stage Ⅰ gastric cancer[J]. Korean J Intern Med, 2021, 36(6):1327-1337.
DOI URL |
[1] | LIU Ruili, LI Lanjun, JIA Minlei, WANG Yihui, HAO Weina. Correlation between tumor miR-7-5p and NOVA2 levels and clinical prognosis in cancer tissues of patients with gastric cancer [J]. Laboratory Medicine, 2023, 38(4): 325-329. |
[2] | GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996. |
[3] | WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881. |
[4] | NIE Tian, RAN Zihan, JIN Lei. Research progress on the relationship between interleukin gene polymorphisms and gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 882-886. |
[5] | YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517. |
[6] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, DONG Wei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Yifei. Expression level of lncRNA SNHG15 in gastric cancer and clinical significance [J]. Laboratory Medicine, 2022, 37(5): 409-412. |
[7] | LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422. |
[8] | CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341. |
[9] | ZHENG Yu, CHEN Jin. Correlation between serum follistatin and clinicopathological characteristics and prognosis of patients with differentiated thyroid cancer [J]. Laboratory Medicine, 2022, 37(11): 1066-1070. |
[10] | XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55. |
[11] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
[12] | HANG Chen, HUANG Biao, PENG Haixia, WEI Xin, XU Weihong, SHENG Huiming, LI Ningli. Role of TRFIA for detecting pepsinogen in screening ulcer gastric cancer [J]. Laboratory Medicine, 2020, 35(7): 721-725. |
[13] | JIN Fangfang, JIN Zizheng, LIU Ning, LOU Jinli. Changes of CD3bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence [J]. Laboratory Medicine, 2020, 35(3): 209-213. |
[14] | ZHOU Fengli, CHU Yimin, LI Ji, YANG Daming, PENG Haixia, XU Ying. LncRNA SNHG1 promoting the growth of gastric cancer through binding to miR-145 [J]. Laboratory Medicine, 2020, 35(10): 1062-1069. |
[15] | CAO Jijun, WANG Jinhu, SHEN Xianjuan, JU Shaoqing. Expression and clinical significance of long noncoding RNA CCAT2 in serum of patients with gastric cancer [J]. Laboratory Medicine, 2019, 34(9): 775-779. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||